Tumor-specific neoantigen presented on Major Histocompatibility Complex (TSNA-MHC) (TSNA-MHC)

Tumor-specific neoantigens (TSNAs) are novel peptides derived from non-synonymous somatic mutations, such as point mutations, insertions, deletions, or gene fusions, that occur exclusively within the tumor genome [1]. These peptides are processed by the intracellular machinery and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules [2]. Once presented, the TSNA-MHC complex serves as a ligand for the T-cell receptor (TCR) of CD8+ or CD4+ T cells, triggering an adaptive immune response [3]. Because TSNAs are absent in healthy tissues, they are highly immunogenic and bypass central thymic tolerance, making them ideal targets for precision immunotherapy with a low risk of systemic autoimmunity [4]. Therapeutic strategies targeting these complexes include personalized cancer vaccines, such as mRNA or peptide-based platforms, and adoptive cell transfer using neoantigen-specific TCR-engineered T cells [2][4]. The clinical utility of targeting TSNA-MHC complexes is currently being explored across various solid tumors, often in combination with immune checkpoint inhibitors to enhance therapeutic efficacy [3].

Other names

NeoantigenNeoepitopeTumor-specific antigenMutation-derived antigenpHLA complexTumor-specific neoepitopeTSNA

Therapeutic agents targeting these complexes function by either delivering the neoantigen (as a vaccine) to stimulate an endogenous T-cell response or by providing engineered T cells (TCR-T) that specifically recognize and kill cells presenting the neoantigen-MHC complex [1][2][4].